1-(9'-ethyl-3'-carbazolyl)-1,2,3,4-tetrahydro-β-carboline

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 哈马拉生物碱
• 英文名称: 1-(9'-ethyl-3'-carbazolyl)-1,2,3,4-tetrahydro-β-carboline
• 英文别名: 1-(9-ethylcarbazol-3-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
• 化学式: C₂₅H₂₃N₃
• 分子量: 365.478
• InChiKey: ASSWMQPRKRHWSP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  28
• 可旋转键数：
  2
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  32.8
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(9'-ethyl-3'-carbazolyl)-1,2,3,4-tetrahydro-β-carboline 在 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 乙醇 、 氯仿 为溶剂， 反应 0.5h， 生成 1-(9'-ethyl-3'-carbazolyl)-3,4-dihydro-β-carboline
  参考文献：
  名称：

  The Preparation and Evaluation of 1-Substituted 1,2,3,4-Tetrahydro- and 3,4-Dihydro-.BETA.-carboline Derivatives as Potential Antitumor Agents

  摘要：

  合成了一系列1-取代的1,2,3,4-四氢-和3,4-二氢-β-卡boline衍生物，并评估了它们对小鼠P-388和人类肿瘤细胞系KB-16、A-549和HT-29的抗肿瘤活性。除化合物19外，所有合成的化合物均表现出显著的细胞毒性。其中，化合物29对所有测试的肿瘤细胞系表现出最强的活性。在1,2,3,4-四氢-β-卡boline和3,4-二氢-β-卡boline之间的细胞毒性并没有明显的相关性。本研究首次发现化合物29作为开发未来抗癌药物的潜在先导。为化合物29提出了抑制机制的假设。

  DOI：

  10.1248/cpb.53.32
• 作为产物：
  描述：

  色胺 、 N-乙基咔唑-3-甲醛 在 三氟乙酸 作用下， 以 甲苯 为溶剂， 反应 48.0h， 生成 1-(9'-ethyl-3'-carbazolyl)-1,2,3,4-tetrahydro-β-carboline
  参考文献：
  名称：

  The Preparation and Evaluation of 1-Substituted 1,2,3,4-Tetrahydro- and 3,4-Dihydro-.BETA.-carboline Derivatives as Potential Antitumor Agents

  摘要：

  合成了一系列1-取代的1,2,3,4-四氢-和3,4-二氢-β-卡boline衍生物，并评估了它们对小鼠P-388和人类肿瘤细胞系KB-16、A-549和HT-29的抗肿瘤活性。除化合物19外，所有合成的化合物均表现出显著的细胞毒性。其中，化合物29对所有测试的肿瘤细胞系表现出最强的活性。在1,2,3,4-四氢-β-卡boline和3,4-二氢-β-卡boline之间的细胞毒性并没有明显的相关性。本研究首次发现化合物29作为开发未来抗癌药物的潜在先导。为化合物29提出了抑制机制的假设。

  DOI：

  10.1248/cpb.53.32

文献信息

• METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS
  申请人：Almstead Neil

  公开号：US20120202763A1

  公开（公告）日：2012-08-09

  Compounds that selectively inhibit pathological production of human vascular endothelial growth factor (VEGF) and compositions comprising such Compounds are described. Compounds that inhibit viral replication or the production of viral RNA or DNA or viral protein and compositions comprising such Compounds are described. Also described are methods of reducing VEGF using such Compounds and methods for treating cancer and non-neoplastic conditions involving the administration of such Compounds. Further described are methods of inhibiting viral replication or the production of viral RNA or DNA or viral protein using such Compounds and methods for treating viral infections involving the administration of such Compounds. The Compounds may be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatments.

  本文介绍了选择性抑制人类血管内皮生长因子（VEGF）病理性产生的化合物以及包含这些化合物的组合物。本文还介绍了抑制病毒复制或病毒RNA或DNA或病毒蛋白质产生的化合物以及包含这些化合物的组合物。同时，本文还介绍了使用这些化合物减少VEGF的方法以及使用这些化合物治疗癌症和非肿瘤性疾病的方法。本文还介绍了使用这些化合物抑制病毒复制或病毒RNA或DNA或病毒蛋白质产生的方法以及使用这些化合物治疗病毒感染的方法。这些化合物可以作为单一治疗剂或与一个或多个其他治疗剂联合使用，用于治疗需要这些治疗的人类。
• METHODS FOR TREATING NEUROFIBROMATOSIS
  申请人：Cao Liangxian

  公开号：US20120157401A1

  公开（公告）日：2012-06-21

  Methods for treating neurofibromatosis involving the administration of a compound that selectively inhibits pathological production of human VEGF are described. The compound can be administered as a single-agent therapy or in combination with one or more additional therapies to a human in need of such treatment.
• METHODS FOR TREATING KAPOSI SARCOMA
  申请人：Cao Liangxian

  公开号：US20120157400A1

  公开（公告）日：2012-06-21

  Methods for treating Kaposi's sarcoma involving the administration of a compound that selectively inhibits pathological production of human VEGF are described. The compound can be administered as a single-agent therapy or in combination with one or more additional therapies to a human in need of such treatment.
• METHODS FOR TREATING BRAIN TUMORS
  申请人：Cao Liangxian

  公开号：US20120157402A1

  公开（公告）日：2012-06-21

  Methods for treating brain tumors involving the administration of a compound that selectively inhibits pathological production of human VEGF are described. The compound can be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatment.
• METHODS FOR TREATING PROSTRATE CONDITIONS
  申请人：Cao Liangxian

  公开号：US20120178707A1

  公开（公告）日：2012-07-12

  Methods for treating prostate cancer involving the administration of a compound that selectively inhibits pathological production of human vascular endothelial growth factor (VEGF) are described. Methods for treating benign prostatic hyperplasia involving the administration of a compound that selectively inhibits pathological production of human VEGF are also described. The compound may be administered as a single-agent therapy or in combination with one or more additional therapies to a human in need of such treatment.